TY - JOUR
T1 - Comparison of thalidomide and lenalidomide as therapy for myelofibrosis
AU - Jabbour, Elias
AU - Thomas, Deborah
AU - Kantarjian, Hagop
AU - Zhou, Lingsha
AU - Pierce, Sherry
AU - Cortes, Jorge
AU - Verstovsek, Srdan
PY - 2011/7/28
Y1 - 2011/7/28
N2 - With the use of the International Working Group for Myelofibrosis Treatment and Research consensus criteria, we reassessed the efficacy of thalidomide and lenalidomide in 125 patients with myelofibrosis treated in 3 consecutive phase 2 trials: 44 received single-agent thalidomide, 41 single-agent lenalidomide, and 40 a combination of lenalidomide plus prednisone. The thalidomide group included significantly more untreated patients and patients with performance status of 2. The Lenalidomide-based therapy produced higher efficacy (34%-38%) than thalidomide (16%; P = .06). Responses to thalidomide were seen within 3-15 weeks, whereas responses to the lenalidomide-based therapy were also seen after a prolonged course of therapy (range, 2-45 weeks). Lenalidomide plus prednisone therapy resulted in significantly longer response duration (median, 34 months) than single-agent lenalidomide or thalidomide (median, 7 and 13 months, respectively; P = .042). Fewer patients (P = .001) discontinued the lenalidomide plus prednisone therapy (13%) because of side effects then patients on single-agents therapy (32%-39%). In conclusion, the combination of lenalidomide plus prednisone appears to be more effective and safer than single-agent thalidomide or lenalidomide.
AB - With the use of the International Working Group for Myelofibrosis Treatment and Research consensus criteria, we reassessed the efficacy of thalidomide and lenalidomide in 125 patients with myelofibrosis treated in 3 consecutive phase 2 trials: 44 received single-agent thalidomide, 41 single-agent lenalidomide, and 40 a combination of lenalidomide plus prednisone. The thalidomide group included significantly more untreated patients and patients with performance status of 2. The Lenalidomide-based therapy produced higher efficacy (34%-38%) than thalidomide (16%; P = .06). Responses to thalidomide were seen within 3-15 weeks, whereas responses to the lenalidomide-based therapy were also seen after a prolonged course of therapy (range, 2-45 weeks). Lenalidomide plus prednisone therapy resulted in significantly longer response duration (median, 34 months) than single-agent lenalidomide or thalidomide (median, 7 and 13 months, respectively; P = .042). Fewer patients (P = .001) discontinued the lenalidomide plus prednisone therapy (13%) because of side effects then patients on single-agents therapy (32%-39%). In conclusion, the combination of lenalidomide plus prednisone appears to be more effective and safer than single-agent thalidomide or lenalidomide.
UR - http://www.scopus.com/inward/record.url?scp=79960999112&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=79960999112&partnerID=8YFLogxK
U2 - 10.1182/blood-2010-12-325589
DO - 10.1182/blood-2010-12-325589
M3 - Article
C2 - 21622644
AN - SCOPUS:79960999112
SN - 0006-4971
VL - 118
SP - 899
EP - 902
JO - Blood
JF - Blood
IS - 4
ER -